摘要
使用MART-1特异性TCR基因治疗的可行性先前已在黑色素瘤患者中被证明。然而,在肝癌(HCC)治疗过程中,没有一个明确的肿瘤特异性抗原仍然是一个挑战。在这项研究中,通过TCR Vβ亚家族和DNA测序克隆扩增的分析,我们确定TCR Vβ7.1_H3F7可作为HCC患者的潜在特异性治疗基因。对于体外肝癌细胞,转染TCRVβ β7.1_H3F7基因的外周血单个核细胞(PBMC )有特异性细胞毒性。对这些转染外周血单个核细胞过继转移将导致动物模型中肝癌肿瘤的发展有显著的抑制。这些结果证明TCRV β7.1_H3F7可作为肝癌特异性治疗基因的价值。更重要的是,它提供了一种新的肿瘤特异性TCR基因的筛选策略,其可以作为目前在癌症患者中没有被界定的肿瘤特异性抗原的TCR基因疗法。
关键词: 肝细胞癌,T细胞受体 , TCR Vβ7.1_H3F7 ,治疗基因
Current Gene Therapy
Title:Identification of Vβ7.1_H3F7 as a Therapeutic Gene Encoding TCR Specific to Hepatocellular Carcinoma
Volume: 14 Issue: 5
Author(s): Shulin Huang, Han Shen, Zhiming Li, Sung-Kay Chiu, Runsheng Ruan, Lanfeng Xiao and Chi-Meng Tzeng
Affiliation:
关键词: 肝细胞癌,T细胞受体 , TCR Vβ7.1_H3F7 ,治疗基因
摘要: The feasibility of T-Cell receptor (TCR) gene therapy using a MART-1-specific TCR has been previously demonstrated in melanoma patients. However, it remains a challenge without a defined tumor-specific antigen in the therapy of hepatocellular carcinoma (HCC). In this study, through the analysis of clonal expansion of TCR Vβ subfamily and DNA sequencing, we identified TCR Vβ7.1_H3F7 as a potential therapeutic gene specifically for the HCC patients. Peripheral blood monouclear cells (PBMC) transfected with TCRV β7.1_H3F7 gene were specifically cytotoxic against HCC cells in vitro. Adoptive transfer of this transfected PBMC resulted in a marked suppression of HCC tumor development in the animal model. These results demonstrated the value of TCRV β7.1_H3F7 as a therapeutic gene specifically for HCC. More importantly, it provides a novel strategy for screening tumor-specific TCR genes, which may pave the way for TCR gene therapy in cancer patients currently without the defined tumor-specific antigens.
Export Options
About this article
Cite this article as:
Huang Shulin, Shen Han, Li Zhiming, Chiu Sung-Kay, Ruan Runsheng, Xiao Lanfeng and Tzeng Chi-Meng, Identification of Vβ7.1_H3F7 as a Therapeutic Gene Encoding TCR Specific to Hepatocellular Carcinoma, Current Gene Therapy 2014; 14 (5) . https://dx.doi.org/10.2174/1566523214666140825124733
DOI https://dx.doi.org/10.2174/1566523214666140825124733 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma
Current Pharmaceutical Biotechnology Bioinformatics and Drug Discovery
Current Topics in Medicinal Chemistry Synthesis of Novel Amides Based on Acridone Scaffold with Interesting Antineoplastic Activity
Anti-Cancer Agents in Medicinal Chemistry Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants
Current Pharmaceutical Design Progress in Nanoparticulate Systems for Peptide, Proteins and Nucleic Acid Drug Delivery
Current Pharmaceutical Biotechnology The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Current Pharmaceutical Design bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design
Current Medicinal Chemistry Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry NBS1 Heterozygosity and Cancer Risk
Current Genomics Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Current Signal Transduction Therapy Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Glatiramer Acetate Induced Hepatotoxicity
Current Drug Safety In Silico Approach to Inhibition of Tyrosinase by Ascorbic Acid Using Molecular Docking Simulations
Current Topics in Medicinal Chemistry Sex-Genetic Interaction in the Risk for Cerebrovascular Disease
Current Medicinal Chemistry Cubosomes: Innovative Nanostructures for Drug Delivery
Current Drug Delivery